Newsletter Subject

This top biotech startup seeking to make a difference

From

bullseyeoptiontrading.com

Email Address

bullseye@b.bullseyeoptiontrading.com

Sent On

Sat, Dec 2, 2023 08:40 PM

Email Preheader Text

Are psychedelics another piece of the PTSD puzzle? ?

Are psychedelics another piece of the PTSD puzzle?                                                                                                                                                                                                                                                                                                                                                                                                                 December 02, 2023 | [Read Online]( This top biotech startup seeking to make a difference [Chat Room](I [Alerts]( I [Follow me on X]( I [Drops Monday]( *Sponsored by Psycheceutical Bioscience Hey Folks– Hope you are in full swing of the holiday spirit! I had a nice time visiting some family over Thanksgiving and even met a fellow RB member, SAM, at the blackjack table. Sam was CRUSHING the most non-traditional blackjack bets I have ever seen 💪 Who would know that traders also like gambling? Nice to meet you, Sam! I have met more members at casinos than anywhere else. Besides a love for casinos, another thing we traders seem to have in common is stress… In my [first interview]( with Chad Harman, CEO of Psycheceutical Bioscience, I semi-joked that most traders likely have PTSD, as our conversation turned to one of the main problems [Psycheceutical]( – our partner in [Boardroom Investing]( – is striving hard to combat. Besides soldiers, it is estimated that [about 13 million]( people struggle with PTSD in a given year! It’s a serious problem without a truly viable solution. Despite the prevalence of mental illness in our world today, current treatments are relying heavily on decades-old technology. The magnitude of this problem needs everything including the kitchen sink thrown at it! That’s where this top biotech startup comes in. [Psycheceutical]( is using cutting-edge patented technologies to bring psychedelics and pharmaceuticals together to create safer and more effective mental health treatments. How is the company doing this? By developing two patented delivery technologies to bring this technology into the current century with its novel administration route and targeted therapeutic effects. You can read more about these technologies and its NeuroDirect™ topical ketamine formula for the treatment of PTSD – that is administered without entering the bloodstream – in this newly released [ARTICLE](, which states: “NeuroDirect’s technology asserts that its topical ketamine formula can hit free nerve endings on the back of the neck, below the hairline, igniting rapid therapeutic relief without dissociation or adverse side effects.” And guess what? The preliminary results are worth celebrating! [Read all about them HERE](. Not only are the initial results for this technology promising, they also could be a GAME CHANGER in terms of cost and accessibility. For decades, scientists have known that psychedelics such as ketamine and psilocybin have powerful potential for lifesaving mental health treatment. The therapeutic use of psychedelics for depression, PTSD, anxiety, and more is a growing industry, with billions of dollars being poured into psychedelic R&D. However, significant medical & technological limitations have kept these medications from being safe, effective, and widely accessible. That’s where Psycheceutical’s groundbreaking new precision-dosing technologies come in, as they’re designed to allow for high bioavailability of compounds to target cells, increased cellular uptake, and provide immediate and sustained symptom relief WITHOUT hallucinogenic effects! The work that this company – trading as BWVI on the OTC market – is doing is truly revolutionary. So what can you do (besides wait in anticipation for this exciting new development?!)? Psycheceutical is seeking investors to come alongside them in their mission to develop this technology and combat the effects of mental health illnesses. They are an early-stage company that relies on investment to continue with Research & Development and would welcome you to join them. If this sounds like something you want to be a part of, you can partner with them through their [Wefunder campaign](. You’ll have access to early bird pricing and more favorable terms. As always, do your own due diligence before you decide to invest in any startup. [A great place to start is here!]( Give this a deep dive and consider the chance to be a part of groundbreaking medical advances to help those affected by mental illnesses. We’re all rooting for you, Chad and Psycheceutical! *Like all investments, this investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull DISCLAIMER: To more fully understand [RagingBull.com](, LLC’s issuer-paid advertisement disclaimer and disclosure policy located at [(. ISSUER-PAID ADVERTISEMENT: This Issuer has paid RagingBull.com, LLC (“Raging Bull”) seventy five hundred dollars in total to run advertisements enhancing public awareness of the company. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. Raging Bull strongly recommends you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this Advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Investing in the private companies discussed in this Advertisement is highly risky. There is currently no market for trading or liquidating the securities discussed in this Advertisement and there is no guarantee that a market will develop in the future. Readers of this Advertisement bear responsibility for their own investment research and decisions and should use information from this Advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money INVESTING OR trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Raging Bull nor any of its owners, employees OR INDEPENDENT CONTRACTORS is CURRENTLY registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. [tw]( Update your email preferences or unsubscribe [here]( © 2023 Bullseye Trades 62 Calef Hwy. #233 Lee, NH 03861, United States of America

Marketing emails from bullseyeoptiontrading.com

View More
Sent On

07/12/2024

Sent On

07/12/2024

Sent On

06/12/2024

Sent On

05/12/2024

Sent On

04/12/2024

Sent On

03/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.